These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 18560130)

  • 1. Pooled analyses on cognitive effects of memantine in patients with moderate to severe Alzheimer's disease.
    Emre M; Mecocci P; Stender K
    J Alzheimers Dis; 2008 Jun; 14(2):193-9. PubMed ID: 18560130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.
    Mecocci P; Bladström A; Stender K
    Int J Geriatr Psychiatry; 2009 May; 24(5):532-8. PubMed ID: 19274640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial.
    Pomara N; Ott BR; Peskind E; Resnick EM
    Alzheimer Dis Assoc Disord; 2007; 21(1):60-4. PubMed ID: 17334274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
    Wilkinson D; Andersen HF
    Dement Geriatr Cogn Disord; 2007; 24(2):138-45. PubMed ID: 17622761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.
    Porsteinsson AP; Grossberg GT; Mintzer J; Olin JT;
    Curr Alzheimer Res; 2008 Feb; 5(1):83-9. PubMed ID: 18288936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer's disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan.
    Nakamura Y; Kitamura S; Homma A; Shiosakai K; Matsui D
    Expert Opin Pharmacother; 2014 May; 15(7):913-25. PubMed ID: 24673497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study.
    Bakchine S; Loft H
    J Alzheimers Dis; 2007 Jul; 11(4):471-9. PubMed ID: 17656827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Memantine for dementia.
    Areosa SA; Sherriff F
    Cochrane Database Syst Rev; 2003; (3):CD003154. PubMed ID: 12917950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
    Tariot PN
    J Clin Psychiatry; 2006; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease.
    Doody R; Wirth Y; Schmitt F; Möbius HJ
    Dement Geriatr Cogn Disord; 2004; 18(2):227-32. PubMed ID: 15256834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
    Riepe MW; Adler G; Ibach B; Weinkauf B; Tracik F; Gunay I
    Dement Geriatr Cogn Disord; 2007; 23(5):301-6. PubMed ID: 17356273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis.
    Schmitt FA; van Dyck CH; Wichems CH; Olin JT;
    Alzheimer Dis Assoc Disord; 2006; 20(4):255-62. PubMed ID: 17132970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease.
    Grossberg GT; Pejović V; Miller ML; Graham SM
    Dement Geriatr Cogn Disord; 2009; 27(2):164-72. PubMed ID: 19194105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Memantine for dementia.
    Areosa SA; Sherriff F
    Cochrane Database Syst Rev; 2003; (1):CD003154. PubMed ID: 12535459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.
    Peskind ER; Potkin SG; Pomara N; Ott BR; Graham SM; Olin JT; McDonald S
    Am J Geriatr Psychiatry; 2006 Aug; 14(8):704-15. PubMed ID: 16861375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Memantine for dementia.
    Areosa Sastre A; McShane R; Sherriff F
    Cochrane Database Syst Rev; 2004 Oct; (4):CD003154. PubMed ID: 15495043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease.
    Ihl R; Ferris S; Robert P; Winblad B; Gauthier S; Tennigkeit F
    Int J Geriatr Psychiatry; 2012 Jan; 27(1):15-21. PubMed ID: 21384431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind, placebo-controlled trial of memantine in age-associated memory impairment (memantine in AAMI).
    Ferris S; Schneider L; Farmer M; Kay G; Crook T
    Int J Geriatr Psychiatry; 2007 May; 22(5):448-55. PubMed ID: 17117395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date.
    Bullock R
    Alzheimer Dis Assoc Disord; 2006; 20(1):23-9. PubMed ID: 16493232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Memantine for dementia.
    McShane R; Areosa Sastre A; Minakaran N
    Cochrane Database Syst Rev; 2006 Apr; (2):CD003154. PubMed ID: 16625572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.